Direitos para esta edição cedidos à Atena Editora pelos autores. Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0).O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais. Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação com base em critérios de neutralidade e imparcialidade acadêmica.A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação, evitando plágio, dados ou resultados fraudulentos e impedindo que interesses financeiros comprometam os padrões éticos da publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.
Background:Stenotrophomonas maltophilia is an emerging pathogen responsible for high morbidity and mortality rates. Hospital infections caused by this bacteria, especially in intensive care centers, are concerning for the health system, given that the microorganism is multidrug resistant to most antimicrobials available. Objective: Therefore, the present study is built from an analysis of the variables related to nosocomial infections caused by S. maltophilia in hospitals in Brazil, to display points of major concern. Methods: We used the data collected by the Infection Prevention and Control Service to clarify the incidence rate of Stenotrophomonas maltophilia in Brazilian hospitals as well as the gross lethality of these infections and the profiles of infected patients. We collected and analyzed epidemiological data from 10 hospitals in Brazil for the period July 2014 to June 2019 according to the CDC NHSN protocol. Results: In 5 years, 93 Stenotrophomonas maltophilia infections were diagnosed in the hospitals analyzed. Overall, 61 occurred in men (66%) and 32 occurred in women (34%). Furthermore, 47 cases (51%) occurred in adult ICUs; 19 cases (20%) followed zascular surgery; 9 (10%) cases occurred in the neonatal ICU; 7 (8%) cases were from the medical clinic; and 11 (12%) were from other clinics. The incidence rate was 1.2 cases for 10,000 hospitalizations, ranging from 0.0 to 2.8 (Fig. 1). Patients’ ages ranged from 0 to 90 years, with a mean of 55 years (SD, 26 years) and a median of 64 years. Time between admission and diagnosis of infection was 1 to 102 days, with a mean of 24 days (SD, 21 days) and a median of 17 days. The gross lethality for S. maltophilia infection was 43 of 93 (46%) (95% CI, 35.8%–56.9%). The frequencies of specific infections were as follows (Fig. 2): pneumonia, 26 (28%); tracheobronchitism, 22 (24%); primary bloodstream infection, 18 (19%); skin and soft-tissue infection, 13 (14%); local infection, 7 (8%); vascular access infection, 3 (3%); urinary tract infection, 2 (2%); gastrointestinal infection, 1 (1%); and eye, nose, throat, and mouth infections, 1 (1%). Conclusions:Stenotrophomonas maltophilia infection is a rare and highly lethal event that usually occurs after 2 weeks of hospitalization. The most affected region is the respiratory tract, with a higher incidence in patients aged >60 years or in the ICU. Early and accurate investigations of multiresistant microorganisms in a hospital setting are needed to reduce patient morbidity and mortality.Funding: NoneDisclosures: None
Background Vancomycin-Resistant Enterococcus (VRE) is considered one of the main pathogens of hospital-acquired infections (HAI), responsible for high morbidity and mortality rates. HAI caused by this bacteria, especially in intensive care units (ICU), are concerning for the health system, given that the microorganism is multi resistant to most antimicrobials available, especially vancomycin. Therefore, the present study is built from and analyzes the data of VRE, collected by the Infection Prevetion and Control Service of hospitals in Brazil, to clarify: the incidence rate, the gross lethality of these infections and what are the profiles of infected patients. Methods Collection and analysis of epidemiological data, according to the National Healthcare Safety Network (NHSN) protocol of the Centers for Disease Control and Prevention (CDC), in 10 hospitals in Brazil, between Jan/2017 - Dec/2019. Results In three years, 118 VRE infections were diagnosed in the hospitals analyzed: 51 from ICU (43%), 24 from Vascular Acess (20%), 18 from General Clinic (15%), 10 from General Surgery (8%) and 15 from Others (13%). Patients ages ranged from 0 to 93 years, with a mean of 62 years (standard deviation of 20 years) and a median of 66 years. Time between admission and diagnosis of infection was 1 to 1001 days, with a mean of 68 days (standard deviation of 25 days) and a median of 59 days. The gross lethality for VRE infections was 47/118 (40%). The infection sites were: Bloodstream Infections – BSI = 34 (29%); Urinary Tract Infections – UTI = 28 (24%); Surgical Site Infections – SSI = 27 (23%); Skin and Soft Tissue Infections – SST = 14 (12%); Bone and Joint Infections – BJ = 5 (4%); Cardiovascular System Infections – CVS = 5 (4%); Lower Respiratory System Infections, other than pneumonia – LRI = 2 (2%); Pneumonia – PNEU = 2 (2%) and Gastrointestinal System Infections – GI = 1 (1%). Percentage of VRE infections by hospital units Percentage of VRE infections by infection sites Infection sites of VRE infections by hospital Conclusion VRE infection is a highly lethal event that usually occurs after two months of hospitalization. The main site of infection is the BSI, with a higher incidence in patients over 62 years or the ones in ICU. Early and accurate investigations of multiresistant microorganisms in a hospital setting are necessary to reduce patient morbidity and mortality. Disclosures All Authors: No reported disclosures
Background: Digital games play an important role in the learning process, and are used to teach languages and train surgeons. Based on theoretical frameworks that prove the relevance of games in teaching, we began developing a computer game that simulates a hospital, so that medical students could analyze clinical cases from different areas of medical science, including neurology, while playing a game. Objectives: Create a game to teach medicine in a ludic manner. Design and Setting: The game is being developed by Doctors, Programmers, Engineers, students of Medicine, Information Technology (IT), Design and Architecture from Brazil and Peru, in a startup incubator from Centro Universitário de Belo Horizonte, in partnership with the Universidad Científica del Sur, Lima, Peru. Methods: Medical students, under the supervision of Doctors, defined behavioral algorithms, based on Brazilian guidelines, and outcomes (i.e. gain or loss of points, clinical improvement or worsening) addressing different topics in Medicine. Design students created the artistic elements. IT students programmed the prototype of the game using Unity software. Results: An expandable minimum viable product was obtained, with artistic elements of two characters, one being a non-playable character, a scenario, and a dialogue script based on a clinical examination of a patient. Conclusion: The software is running, with the launch of the pre-alpha version in December 2021. A scoring system will be included for qualitative assessment of the player, as well as feedback reports to educate the player. We speculate this game will improve accuracy and clinical skills of medical students.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.